Search

Your search keyword '"Kelley, Michael J."' showing total 317 results

Search Constraints

Start Over You searched for: Author "Kelley, Michael J." Remove constraint Author: "Kelley, Michael J." Database Unpaywall Remove constraint Database: Unpaywall
317 results on '"Kelley, Michael J."'

Search Results

1. “PMS2CL interference leading to erroneous identification of a pathogenic PMS2 variant in Black Patients”

2. Oncogenic alteration rates, race, and prostate cancer specific mortality in Veterans with metastatic prostate cancer undergoing somatic tumor next generation sequencing.

3. Incidence of germline genetic testing in Veterans with breast cancer in the Veterans Health Administration.

4. Implementing a natural language processing pipeline to expedite clinical chart review to assess germline genetic testing in veterans with breast cancer.

6. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)

8. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer

13. On-Site Nurse-Led Cancer Genetics Program Increases Cancer Genetic Testing Completion in Black Veterans

15. Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans

16. Supplementary Table 2 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

17. Supplementary Table 2 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

18. Supplementary Figure 3: VAC14 Heterozygous Mice are Sensitive to Nociceptive Stimuli from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

19. Supplementary Figure 2: VAC14 Knockdown and neuronal cell sensitivity to docetaxel or paclitaxel for additional morphological phenotypes from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

20. Supplementary Table 3 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

21. Supplementary Table 1 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

22. Supplementary Figure 1: Patient Disposition from Clinical Trial to Pharmacogenetic Analysis from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

25. Veterans Health Administration National TeleOncology Service

30. Researcher experience and comfort with telemedicine and remote patient monitoring in cancer treatment trials.

31. Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program

45. Metastatic bulk to predict subclonal heterogeneity by ctDNA in RAS/RAF-wildtype colorectal cancer.

47. Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites

49. Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer

50. Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program

Catalog

Books, media, physical & digital resources